Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wouter P Te Rijdt

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
JACC. Cardiovascular Imaging|November 22, 2020
Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of SymptomsKarim Taha, Wouter P Te Rijdt, Tom E Verstraelen, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|August 1, 2017
Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathyWouter P Te Rijdt, Z Joy van der Klooster, Edgar T Hoorntje, et al.
European Heart Journal. Cardiovascular Imaging|September 13, 2021
Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriersKarim Taha, Tom E Verstraelen, Remco de Brouwer, et al.
International Journal of Cardiology|May 8, 2025
High incidence of malignant arrhythmias and heart failure in patients with RBM20-associated cardiomyopathy: A multicenter cohort study and review of the literatureMartijn Tukker, Wouter P Te Rijdt, Ahmad S Amin, et al.
Circulation|April 30, 2021
Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del CardiomyopathyDries A M Feyen, Isaac Perea-Gil, Renee G C Maas, et al.
Virchows Archiv : an International Journal of Pathology|March 10, 2023
Genetically determined cardiomyopathies at autopsy: the pivotal role of the pathologist in establishing the diagnosis and guiding family screeningMary N Sheppard, Allard C van der Wal, Jytte Banner, et al.
European Journal of Heart Failure|October 24, 2017
The first titin (c.59926 + 1G > A) founder mutation associated with dilated cardiomyopathyEdgar T Hoorntje, Karin Y van Spaendonck-Zwarts, Wouter P Te Rijdt, et al.
Scientific Reports|June 20, 2020
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapyTim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, et al.
Scientific Reports|October 3, 2020
Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapyTim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, et al.
European Heart Journal. Cardiovascular Imaging|April 11, 2018
Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imagingWouter P Te Rijdt, Judith N Ten Sande, Thomas M Gorter, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
JACC. Cardiovascular Imaging|November 22, 2020
Early Mechanical Alterations in Phospholamban Mutation Carriers: Identifying Subclinical Disease Before Onset of SymptomsKarim Taha, Wouter P Te Rijdt, Tom E Verstraelen, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|August 1, 2017
Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathyWouter P Te Rijdt, Z Joy van der Klooster, Edgar T Hoorntje, et al.
European Heart Journal. Cardiovascular Imaging|September 13, 2021
Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriersKarim Taha, Tom E Verstraelen, Remco de Brouwer, et al.
International Journal of Cardiology|May 8, 2025
High incidence of malignant arrhythmias and heart failure in patients with RBM20-associated cardiomyopathy: A multicenter cohort study and review of the literatureMartijn Tukker, Wouter P Te Rijdt, Ahmad S Amin, et al.
Circulation|April 30, 2021
Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del CardiomyopathyDries A M Feyen, Isaac Perea-Gil, Renee G C Maas, et al.
Virchows Archiv : an International Journal of Pathology|March 10, 2023
Genetically determined cardiomyopathies at autopsy: the pivotal role of the pathologist in establishing the diagnosis and guiding family screeningMary N Sheppard, Allard C van der Wal, Jytte Banner, et al.
European Journal of Heart Failure|October 24, 2017
The first titin (c.59926 + 1G > A) founder mutation associated with dilated cardiomyopathyEdgar T Hoorntje, Karin Y van Spaendonck-Zwarts, Wouter P Te Rijdt, et al.
Scientific Reports|June 20, 2020
The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapyTim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, et al.
Scientific Reports|October 3, 2020
Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapyTim R Eijgenraam, Bastiaan J Boukens, Cornelis J Boogerd, et al.
European Heart Journal. Cardiovascular Imaging|April 11, 2018
Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imagingWouter P Te Rijdt, Judith N Ten Sande, Thomas M Gorter, et al.
Pageof 3